Verrica Pharmaceuticals INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Affinity Asset Advisors, LLC and Michael Cho have disclosed a 5.5% beneficial ownership stake in Verrica Pharmaceuticals Inc., including shares from warrants.
NASDAQ
Affinity Asset Advisors, LLC and Affinity Healthcare Fund, LP have disclosed a combined beneficial ownership of 5.47% in Verrica Pharmaceuticals Inc.
NASDAQ
Armistice Capital and Steven Boyd have reported a 6.77% beneficial ownership stake in Verrica Pharmaceuticals Inc., holding 639,193 shares.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9.99% of Verrica Pharmaceuticals Inc.'s common stock as of March 31, 2025.
NASDAQ
Perceptive Advisors LLC and its affiliated entities have filed an amended Schedule 13G, disclosing a 1.6% beneficial ownership stake in Verrica Pharmaceuticals, Inc., holding 1,481,481 shares through pre-funded warrants.
NASDAQ
Armistice Capital, LLC and Steven Boyd have jointly disclosed a beneficial ownership of 9.99% in Verrica Pharmaceuticals Inc., totaling 9,235,571 shares of common stock.
NASDAQ
SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose Nearly 10% Stake in Verrica Pharmaceuticals
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.99% in Verrica Pharmaceuticals Inc., totaling 9,134,817 shares of common stock.
NASDAQ
Perceptive Advisors and its affiliated entities have reported a 5.1% beneficial ownership stake in Verrica Pharmaceuticals Inc., totaling 4,731,150 shares, as of December 31, 2024.
NASDAQ
Caligan Partners LP and David Johnson have disclosed a 9.99% beneficial ownership stake in Verrica Pharmaceuticals Inc., including shares issuable from warrants, as of December 31, 2024.